Platelet Activation and Reactivity in Acute Exacerbations of COPD

Platelet Activation and Responsiveness in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03017625

Enrollment

Registered

2017-01-11

Start date

2017-01-31

Completion date

2017-09-30

Last updated

2017-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD Exacerbation

Keywords

COPD, Cardiovascular Disease, Platelets, Inflammation

Brief summary

Chronic obstructive pulmonary disease (COPD) is known for development of severe cardiovascular co-morbidities. Systemic inflammation during acute exacerbations of COPD (AE-COPD) is thought to play a role in development of cardiovascular disease. Platelets contribute to acute cardiovascular events and atherosclerosis. When platelets are activated, they form complexes with monocytes. These platelet-monocyte complexes (PMCs) are an early process in atherothrombosis and promote inflammation. In COPD, platelet function in AE-COPD is scarcely studied. This study aims to address this gap by investigating platelet function and coagulation in patients with AE-COPD and after convalescence.

Interventions

OTHERBlood is drawn

Blood analyses

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 99 Years

Healthy volunteers

Inclusion criteria

* \>40 years * Spirometry confirmed diagnosis of COPD (i.e. post-bronchodilator FEV1/FVC \< 70% and less than 12% on reversibility testing\< Lower limit of normal (LLN)) * ≥10 pack years of smoking

Exclusion criteria

* Use of anti-coagulation or other platelet function inhibitors * Asthma * Chronic inflammatory diseases, for example rheumatoid arthritis, psoriasis, inflammatory bowel diseases , systemic lupus erythematous (SLE) * Malignancies

Design outcomes

Primary

Measure	Time frame
Platelet activation: platelet expression of CD62P (P-selectin) and fibrinogen binding at baseline and upon ex vivo stimulation.	Measured at presentation with an AE-COPD and after 8 weeks

Secondary

Measure	Time frame
Platelet-monocyte interaction (CD14 cells positive for CD61)	Measured at presentation with an AE-COPD and after 8 weeks
Monocyte activation (CD11b expression on CD14 positive cells)	Measured at presentation with an AE-COPD and after 8 weeks
Tissue factor triggered thrombin generation capacity	Measured at presentation with an AE-COPD and after 8 weeks
Plasma markers: Interleukin-6, Interleukin-8, high sensitive-CRP, soluble P-selectin, soluble Fibrinogen, D-dimer	Measured at presentation with an AE-COPD and after 8 weeks

Contacts

Primary ContactFloor E Aleva, MD

floor.aleva@radboudumc.nl0031 24 361 03 25

Backup ContactYvonne F Heijdra, MD, PhD

yvonne.heijdra@radboudumc.nl0031 24 361 03 25

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026